MAPT and Alzheimer disease: Remarkably, emerging evidence strongly correlates CSF amyloidβ (Aβ42), phospho-tau (p-tau), total-tau (t-tau) levels and AD neuropathological lesions, establishing CSF biomarkers as critical for early AD detection with high diagnostic accuracy (Masters et al., 2015; Jack et al., 2018).